Navigation Links
Newport Corporation to Present at B. Riley & Co. Investor Conference Tomorrow, May 25
Date:5/24/2010

IRVINE, Calif., May 24 /PRNewswire-FirstCall/ -- Newport Corporation (Nasdaq: NEWP) today announced that it will present at the B. Riley & Co. Investor Conference tomorrow, May 25, 2010, at 3:30 pm Pacific time (6:30 pm Eastern time).  Newport will make its presentation in the Palisades C Room of Loews Santa Monica Beach Hotel in Santa Monica, Calif.

The 25-minute presentation by Senior Vice President and Chief Financial Officer Charles F. Cargile can be heard through a live audio webcast available at www.newport.com/investors and http://www.wsw.com/webcast/brileyco14/newp/. This webcast will be archived for 90 days on both web sites.

About Newport Corporation

Newport Corporation is a leading global supplier of advanced-technology products and systems to customers in the scientific research, microelectronics, aerospace and defense/security, life and health sciences, and precision industrial manufacturing markets. Newport's innovative solutions leverage its expertise in lasers, photonics instrumentation, sub-micron positioning systems, vibration isolation, optical components and subsystems, and precision automation
'/>"/>

SOURCE Newport Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, ... Partners, today announced the hiring of veteran equity analyst ... equity analyst. Mr. Butler will focus on the biotech/biopharma ... team a wealth of experience and a broad network ... , Senior Managing Director and Head of Equities at ...
(Date:8/27/2014)... 27, 2014 Flagship Biosciences LLC, a ... to the pharmaceutical and medical device industries, has announced ... fast growing company has consolidated its histology and tissue ... to Westminster, CO, just north of Denver. The ... W. 103rd Ave., Suite 100, Westminster, CO 80021 , ...
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 ... state of the global isotope ratio mass spectrometer industry. ... the industry including definitions, classifications, applications and industry chain ...
(Date:8/27/2014)... Tris Pharma, a specialty pharmaceutical company focused ... it has been selected as an award winner in ... Awards for Excellence competition in the Business Expansion ... judges from SCORE (Counselors to America,s Small Business) and ... at a gala event to be held on October ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... Spherix Incorporated (Nasdaq: SPEX ), an ... and atherosclerosis; and providers of technical and regulatory consulting ... announced the close of previously reported agreements to sell ... Preferred Stock and warrants to purchase shares of its ...
... Agreement on Molecular Tests... -- GERMANTOWN, Maryland and DES PLAINES, Illinois, October 12, 2010, ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 2QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 3QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 4QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 5QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 6QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 7QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 8QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 9QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 10US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5
(Date:8/28/2014)... pose a significant health risk to people with asthma according ... Allergy and Clinical Immunology . , By critically reviewing the ... has found that the presence of several types of mould ... as increasing the likelihood of developing the condition. , The ... of Exeter Medical School and is the first time all ...
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
(Date:8/27/2014)... bears, giant ground sloths, saber-toothed cats and American camels ... at the end of the Pleistocene period. The cause ... scientists who, until recently, could only speculate as to ... Barbara,s James Kennett, professor emeritus in the Department of ... played a major role in the extinction. Their hypothesis ...
Breaking Biology News(10 mins):Indoor mold poses health risk to asthma sufferers 2Paleontology: Oldest representative of a weird arthropod group 2Nanodiamonds are forever 2Nanodiamonds are forever 3
... News headlines are filled with discussion and ... Change Conference in Copenhagen. As expected, the ... has focused on traditional environmental measures - regulations ... sources, etc. A new book Paradise Regained: ...
... PHILADELPHIA People with the heritable disorder of ... to develop basal cell carcinoma of the skin may ... According to results of a placebo-controlled, randomized, double-blind, ... in inhibiting the development of basal cell carcinomas in ...
... plan to put two and two together in a study ... Two traits that impact corn will be examined by ... products at the farm level. Drought tolerance and aflatoxin ... Research scientists who have been awarded a $500,000 grant for ...
Cached Biology News:Global warming and other environmental dangers may be solved by unlikely source -- space technology 2Celebrex inhibited the burden of skin cancer in high-risk patients 2Genes for drought-tolerance, aflatoxin may mingle to boost corn production 2
... synthetic peptide whose sequence is from rat SCAMP 5. The ... - N(217) - Q - P - Q - T - ... - N - Y - T - Y - S - ... control experiments with the polyclonal antibody that reacts with this product ...
... of IgY) , After we receive your antigen ... the appropriate number of chickens and begin to ... collected (usually over a period of 3-5 days), ... total of four injections into the breast muscle. ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
Biology Products: